We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Drug Developers Urged to Adopt Humans as Superorganism Approach

By LabMedica International staff writers
Posted on 26 Jul 2012
A recent review article summarized more than 100 studies relating to the concept that humans are actually “superorganisms” composed of many varieties of eukaryotic and prokaryotic cells.

Most drug development activities have been conducted within a framework that links a single drug with its critical receptor target. More...
However, this approach may change due to increasing interest in understanding the properties of traditional Chinese medicines (TCMs) for their potential utilization as a source of new drugs, since emerging evidence indicates that most TCM drugs are actually targeting both the human host and many of its symbiotic microbes.

Chinese medicine traditionally viewed humans as “superorganisms” comprised of only about 10% human cells with the other 90% of the body being composed of bacterial, fungal, and other cells. These symbiotic microorganisms release molecular signals that can determine whether human genes turn on or off and that can influence the immune system's defenses against disease.

To better understand the superorganism concept investigators at Shanghai Jiao Tong University (Shanghai, China) reviewed more than 100 studies related to this topic in a paper that was published in the July 6, 2012, issue of the Journal of Proteome Research. In this review, they explored the challenges of and opportunities for harmonizing Eastern–Western drug discovery paradigms by focusing on emergent functions at the whole body level of humans as superorganisms.

“This superorganism view of the human body provides a complete new systems concept for managing human health at the clinically relevant whole body level,” said the authors. “It is one of the most significant paradigm shifts in modern medicine."

The review described how this revolutionary change is fostering emergence of an approach called "functional metagenomics" for developing new medicines. This could lead to new drug candidate compounds for chronic diseases targeting receptors outside the currently accepted “druggable genome” and shed light on current high interest issues in Western medicine such as drug-drug and drug-diet-gut microbial interactions that will be crucial in the development and delivery of future therapeutic regimes optimized for the individual patient.

Related Links:

Shanghai Jiao Tong University





Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.